Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. - Wikidata - wikimedia - TriplyDB

Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.

Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.

http://www.wikidata.org/entity/Q34287840

about

The search for novel analgesics: targets and mechanisms Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception A lipid gate for the peripheral control of pain Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism The role of long chain fatty acids and their epoxide metabolites in nociceptive signaling Soluble epoxide hydrolase: gene structure, expression and deletion Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor selectivity and dimer formation Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men Dysregulation of soluble epoxide hydrolase and lipidomic profiles in anorexia nervosa Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats An ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosis Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model Method for Sorting and Pairwise Selection of Nanobodies for the Development of Highly Sensitive Sandwich Immunoassays Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern Potent natural soluble epoxide hydrolase inhibitors from Pentadiplandra brazzeana baillon: synthesis, quantification, and measurement of biological activities in vitro and in vivo Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.Linoleic acid participates in the response to ischemic brain injury through oxidized metabolites that regulate neurotransmission.An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension.Rationally designed multitarget agents against inflammation and pain.Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.Metabolic phenotyping reveals a lipid mediator response to ionizing radiation Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids.Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA.Role of epoxide hydrolases in lipid metabolism ω-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.Comparison of the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and esterified oxylipins Expression and characterization of an epoxide hydrolase from Anopheles gambiae with high activity on epoxy fatty acids.

P2860

Q24288817-5144FEE9-F783-468D-B708-6F773F6BF672 Q24616753-D720AEC5-8F33-4CAD-B3B4-E5F2EF979CAC Q24618018-48FE90FA-3ECB-4AE8-BFBA-B867EDBD5E45 Q24628660-C2B789E4-2C26-429F-AA92-D671F7313F8C Q26995053-FDEB7005-A29F-490C-8934-D6641AE0DC61 Q27014988-5154A3C7-2837-4C33-856E-F22F64C39358 Q27678172-7B32F1A9-C589-4FB7-9A9D-19D98B13C35E Q27684895-DFD6EDC0-9CD4-40BB-91DD-D549BDAC52C0 Q28235974-D1142D78-561A-455D-B904-65E1430CE46D Q28245279-275CDF1B-4157-4267-BEB2-FC04DF162448 Q28248377-552101A6-7236-428B-BA31-540A24B14045 Q28291292-4A0EF7E4-252D-4BE2-AE93-F67FF5B29FEC Q28304230-BC8CE7D4-6F77-4619-853E-6DE8DD881C4B Q28385478-4BDFE20A-450A-42B8-BEC6-D2C7BD9A460A Q28386561-F1FDA5AF-62D5-4EF2-86D0-6532E8FD51B0 Q28387829-720B932F-274E-4D7D-A836-39F71644C291 Q28390115-597E1F7D-6DCA-4EBF-B053-B0C3801AE40C Q28392212-901967BB-6AFB-4D89-9A3B-FF96A4BCF824 Q28392416-110DE1EB-27C4-4099-97DA-7276089BFF33 Q28392609-4D7AD901-8969-4F70-9D83-378956745FA2 Q28393724-001993DF-4CC7-4510-AE50-385F3C49E759 Q28393751-7E5C700C-8820-44C8-B03A-6DD9FE4FC03A Q28395323-E68A36D8-DE21-4C80-9EF5-0B83206B28E6 Q28395341-39D8FF99-C19C-4F10-AC04-FD47DAC46F7F Q28396233-645AE2BE-656D-47E8-ADED-49DB92989C24 Q28397238-DC9F4805-28AC-4E8E-8B8E-75FBD40E042A Q28543232-76D4476C-1814-4150-8776-AD8FA5F4768A Q33740554-1C6AED38-F861-4A83-9BAD-F0D896232A44 Q33849059-B6042708-77B7-49C7-AB79-E0ACAF8E1A4A Q33882374-3D1463BD-2A1F-4695-BF3E-DBF40F844E17 Q33960685-A86A09DC-589A-43F1-AC79-5753469CCEAF Q34115301-BC199452-D7E2-4051-894A-C9BB3C7D8202 Q34141817-6267BE83-727B-4D79-B917-95870EF643E2 Q34183871-BB42962E-22CB-4AF9-9E11-F5B68AE2F430 Q34231280-2049B886-3C7A-4928-93B8-30AE237749D0 Q34283241-A11A97E9-E73E-4738-9F2A-0E92A7AEB4E5 Q34428959-4C6FEA12-61FE-4A26-A0FF-213AFB58A174 Q34515993-C9A1F23C-DE18-454B-AAA2-68C062C5E239 Q34587774-AFD31A89-BA85-4527-B3EF-577D791E6AB6 Q34616321-66DACBAD-8D01-4FDA-AE98-23AB8552CD54

P2860

Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids.

http://www.wikidata.org/entity/Q34287840

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@ast

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@en

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@nl

type

label

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@ast

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@en

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@nl

prefLabel

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@ast

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@en

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@nl

P1433

Q34287840-C9D9CF84-6AB6-40B6-857E-E23B6A073ECE

P1476

Q34287840-716123CA-0416-4E25-9CD9-05CBA17C6B69

P2093

Q34287840-1A69F37F-04D8-46AB-AC13-5CEED72E7D2C

Q34287840-C25280E6-3828-4947-BD21-293048F7021E

Q34287840-ED0FBA29-FFB3-4263-95F2-CA1CEA08644E

Q34287840-ED783A62-BE5D-4D92-9615-A1214FD66A3A

Q34287840-F36E0AE0-E267-479F-99A0-9AAA031CC7B5

Q34287840-F55EB791-F8D4-4BCD-A20E-6A652A838D9A

P2860

Q34287840-03BFBCA3-16BE-44A3-845F-26F1ACF30EB2

Q34287840-056BF0F9-135F-4641-AFE0-4894C668D940

Q34287840-08DF53D1-B407-40D1-B95E-26A6237FC943

Q34287840-116F90E7-026E-4E58-878A-29F4671DED49

Q34287840-1267E6BA-407E-4814-A8CB-642111AAFE50

Q34287840-199A9E83-1625-4917-9F61-44563F1A63E9

Q34287840-23B77051-323E-424B-87ED-EEAB34C91EA5

Q34287840-27F549A4-B011-4E1C-9F1A-EF024919D010

Q34287840-2A374AEC-46E0-4FFC-A346-07B10E295908

Q34287840-2D86ACC9-C7F7-463D-9D75-182E1CF45E32

P304

Q34287840-F23CD945-3E45-40E2-8B69-6C15D118EE71

P31

Q34287840-FD73CA91-CF71-458E-80E4-7DDAA30F7ACD

P356

Q34287840-90D955CE-696E-41ED-A706-B279BA355FDE

P433

Q34287840-E824C6BC-560E-4A27-A59E-F97852E90D0E

P478

Q34287840-764DA8CC-550D-421C-8071-3AD6392B67F2

P50

Q34287840-5593FCC1-BA6F-48D6-A9ED-7E644637C02D

P577

Q34287840-8166DAB0-87D3-492E-8DDD-4157651EBA35

P5875

Q34287840-0C206192-2A79-49C4-9D97-23E4B4C5E863

P698

Q34287840-42E30A68-755E-4EBD-935A-C43606DBEAE3

P932

Q34287840-8FA29C2D-A665-445A-BE39-2579BE56BFF2

P356

P1433

Journal of Lipid Research

P1476

Naturally occurring monoepoxid ...... ctive antihyperalgesic lipids.

@en

P2093

Bruce D Hammock

http://www.w3.org/2001/XMLSchema#string

Christine M Hegedus

http://www.w3.org/2001/XMLSchema#string

Christophe Morisseau

http://www.w3.org/2001/XMLSchema#string

Hsing-Ju Tsai

http://www.w3.org/2001/XMLSchema#string

Kara Schmelzer

http://www.w3.org/2001/XMLSchema#string

Steven L Jinks

http://www.w3.org/2001/XMLSchema#string

P2860

cDNA cloning and expression of a soluble epoxide hydrolase from human liver

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase

Epoxide hydrolases: their roles and interactions with lipid metabolism

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent

Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain

Resolution of inflammation: the beginning programs the end

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.

Effect of fish oils containing different amounts of EPA, DHA, and antioxidants on plasma and brain fatty acids and brain nitric oxide synthase activity in rats.

P304

3481-3490

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1194/JLR.M006007

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45389028

http://www.w3.org/2001/XMLSchema#string

P698

20664072

http://www.w3.org/2001/XMLSchema#string

P932

2975720

http://www.w3.org/2001/XMLSchema#string